title: Dopaminergic D2-like agonists produce yawning in the myelin mutant taiep and Sprague-Dawley rats.
abstract: Systemic administration of D2-like dopaminergic-receptor agonists increases yawning behavior. However, only a few studies have been done in animals with pathological conditions. The taiep rat is a myelin mutant with an initial hypomyelination followed by progressive demyelination, being the brainstem one of the most affected areas. In our experiments, we analyzed the effects of systemic administration of the D2-family agonists and antagonists on yawning behavior, and correlated them with the lipid myelin content in the brainstem and other areas in the central nervous system (CNS) in 8 month old male taiep and Sprague-Dawley rats. Subjects were maintained under standard conditions in Plexiglas cages with a 12:12 light-dark cycle, lights on at 0700 and free access to rodent pellets and tap water. Drugs were freshly prepared injected ip at 0800 and subjects were observed for 60 min. When antagonists were used it was administered 15 min before the agonist. Sprague-Dawley and taiep rats significantly increased their yawning frequency after systemic injection of (-)-quinpirole hydrochloride, R(+)-7-Hydroxy-2-(dipropylamino)tetralin hydrobromide (7-OH-DPAT) or trans-(±)-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol hydrochloride ((±)-PD 128,907). Among D2-like agonists used higher effects are obtained with (-)-quinpirole. The effects caused by (-)-quinpirole can be reduced by (-)-sulpiride; and yawning caused by 7-OH-DPAT was decreased by tiapride only in taiep rats. In Sprague-Dawley only (-)-sulpiride is able to decrease (-)-quinpirole-caused yawning. In conclusion, dopaminergic D2-like agonists are still able to cause yawning despite the severe myelin loss in taiep rats. Similarly, patients with various CNS illnesses that affect myelin, such as stroke or multiple sclerosis, are able to yawn suggesting that trigger neurons are still able to command this innate behavior.
authors.affiliation: Instituto de Fisiología, Benemérita Universidad Autónoma de Puebla, Apdo. Postal 5-66, Puebla, Pue. CP 72430, Mexico. jose.eguibar@correo.buap.mx
authors.forename: Jose R
authors.initials: JR
authors.lastname: Eguibar
authors.forename: Ma del Carmen
authors.initials: Mdel C
authors.lastname: Cortes
authors.forename: Manuel
authors.initials: M
authors.lastname: Lara-Lozano
authors.forename: Diana M
authors.initials: DM
authors.lastname: Mendiola
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D003711:Demyelinating Diseases / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D018450:Disease Progression; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000494:pharmacology; D006429:Hemiplegia / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D008297:Male; D009186:Myelin Sheath / Q000187:drug effects / Q000235:genetics / Q000473:pathology; D051381:Rats; D011922:Rats, Mutant Strains; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000819:agonists* / Q000235:genetics / Q000502:physiology*; D015000:Yawning / Q000187:drug effects / Q000235:genetics*
chemical_list: D018491:Dopamine Agonists; D017448:Receptors, Dopamine D2